The effect of hepatitis C virus treatment on ovarian reserve

Midan, Mahmoud Farouk; Eid, Samia Mohamed; El-Latif, Mahmoud A.

doi:10.18203/2320-1770.ijrcog20160572

“…At the end of treatment 28% of studied cases remained in pretreatment level of AMH, in 32% of studied cases AMH decreased, whereas in 40% of cases it increased. Thus they concluded that the IFN and ribavirin affect ovarian reserve in treated patients as in 72% of patients change of AMH levels occurred [19] .…”

Section: Introductionmentioning

confidence: 97%

Advances in HCV Treatment-Effect of HCV Infection/HCV Treatment (Peg-Ifn/Ribavirin) on Fertility (Ovarian Reserve)

KocharKaur¹,

Allahbadia²,

Singh³

2017

JGNB

0

View full text Add to dashboard Cite

Hepatists C Virus is a RNA virus belonging to the Fl aviriridae family. It has been seen in previous studies that HCV infection perse is associated with reduced ovarian reserve and higher cycle cancellation rate in ovarian cycles. Simultaneously treatment of HCV with Pegylated Interferon (PEG-IFN) and ribavirin (RBV) is known to affect the ovarian reserve. Although there are some controversial reports regarding effect of HCV on fertility. Some guidelines have been laid regarding on co-fertility situations where prior to starting treatment cryopreservation of oocytes/embryos should be done by doing an IVF cycle. We discuss such controversial issues in a case who had chronic HCV infection affecting liver function besides bad obstetric disease and needed antiviral therapy for Chronic HCV infection affecting liver function, but whether at her age was doing cryopreservation indicated or justified in view of her age and known effects of HCV treatment on future fertility and risk of spread. We also review the modern advancements in the treatment of HCV infection and their future effects on fertility.

show abstract

“…It is mandatory to evaluate the safety of certain drugs on ovarian toxicity, as any morphological abnormities induced in the ovaries cause impairment of the female reproductive cycle [5]. The old HCV treatment regimen: interferon and ribavirin, were shown to affect the ovarian reserve in treated women [6]. There are no studies on the effect of SOF on ovarian tissue or function yet, and it is the aim of this study.…”

Section: Introductionmentioning

confidence: 99%

Effect of Sofosbuvir on rats’ ovaries and the possible protective role of vitamin E: biochemical and immunohistochemical study

Ebrahim,

Abdalla,

Yassin

et al. 2023

Anat Cell Biol

1

0

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a major health problem worldwide and its eradication is mandatory. Direct acting HCV polymerase inhibitors, such as Sofosbuvir (SOF), is an effective regimen. However, it has some side effects like mutagenesis, carcinogenesis, and the impairment of testicular function. It is important to evaluate the safety of SOF on the ovary, as there are no studies yet. Increasing the production of Reactive Oxygen Species (ROS), causes oxidative stress, which affects ovulation process, female reproduction, and fertility. Accumulation of SOF in the cells was demonstrated to promote ROS generation. Vitamin E (Vit E) is an antioxidant agent that has an essential role in the female reproductive system, its deficiency can cause infertility. We explored the effect of SOF treatment alone and co-treated with Vit E on ovarian ROS level and ovarian morphology experimentally using biochemical and immunohistochemical studies. Significant changes in oxidative stress markers; nitric oxide and malondialdehyde lipid peroxidation, antioxidant enzymes; catalase, super oxide dismutase, and reduced glutathione, proliferating markers; proliferation cell nuclear antigen and Ki-67 antigen and caspase 3 apoptotic marker were demonstrated. It was shown that where SOF induced oxidative stress, it also aggravated ovarian dysfunction. The essential role of Vit E as an antioxidant agent in protecting the ovarian tissue from the effect of oxidative stress markers and preserving its function was also displayed. This could be guidance to add Vit E supplements to SOF regimens to limit its injurious effect on ovarian function.

show abstract

Advances in HCV Treatment-Effect of HCV Infection/HCV Treatment (Peg-Ifn/Ribavirin) on Fertility (Ovarian Reserve).

Kaur¹,

Allahbadia²,

Singh³

2017

JGNB

1

0

View full text Add to dashboard Cite

Hepatists C Virus is a RNA virus belonging to the Fl aviriridae family. It has been seen in previous studies that HCV infection perse is associated with reduced ovarian reserve and higher cycle cancellation rate in ovarian cycles. Simultaneously treatment of HCV with Pegylated Interferon (PEG-IFN) and ribavirin (RBV) is known to affect the ovarian reserve. Although there are some controversial reports regarding effect of HCV on fertility. Some guidelines have been laid regarding on co-fertility situations where prior to starting treatment cryopreservation of oocytes/embryos should be done by doing an IVF cycle. We discuss such controversial issues in a case who had chronic HCV infection affecting liver function besides bad obstetric disease and needed antiviral therapy for Chronic HCV infection affecting liver function, but whether at her age was doing cryopreservation indicated or justified in view of her age and known effects of HCV treatment on future fertility and risk of spread. We also review the modern advancements in the treatment of HCV infection and their future effects on fertility.

show abstract

The effect of hepatitis C virus treatment on ovarian reserve

Cited by 3 publications

References 32 publications

Advances in HCV Treatment-Effect of HCV Infection/HCV Treatment (Peg-Ifn/Ribavirin) on Fertility (Ovarian Reserve)

Advances in HCV Treatment-Effect of HCV Infection/HCV Treatment (Peg-Ifn/Ribavirin) on Fertility (Ovarian Reserve)

Effect of Sofosbuvir on rats’ ovaries and the possible protective role of vitamin E: biochemical and immunohistochemical study

Advances in HCV Treatment-Effect of HCV Infection/HCV Treatment (Peg-Ifn/Ribavirin) on Fertility (Ovarian Reserve).

Contact Info

Product

Resources

About